Granules India's Gagillapur and Jeedimetla facilities located at Hyderabad, Telangana, has completed the US Food and Drug Administration (USFDA) inspection from March 19, 2018 to March 23, 2018 without any 483 observations for Gagillapur facility and with one 483 observation for Jeedimetla facility. The company will respond to this observation within the stipulated time period.
Gagillapur facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs) whereas Jeedimetla facility manufactures Active pharmaceutical ingredients (APIs) and Pharmaceutical Formulation Intermediates (PFIs).
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.05 |
Dr. Reddys Lab | 1354.20 |
Cipla | 1470.05 |
Lupin | 2190.50 |
Zydus Lifesciences | 1004.05 |
View more.. |